跳至主要内容
临床试验/DRKS00027579
DRKS00027579尚未招募不适用

Immunogenicity of a recombinant zoster vaccine (RZV) against herpes zoster (HZ) in adults with rheumatic diseases (SECTORED) - SECTORED

St. Elisabeth Gruppe GmbH Katholische Kliniken Rhein-Ruhr0 个研究点目标入组 150 人开始时间: 2022年2月8日最近更新:

试验速览

阶段
不适用
状态
尚未招募
入组人数
150

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
18 Years 至 one(—)
性别
All

入选标准

  • Male and female patients aged 18 years and older who are at increased risk to develop HZ
  • - Diagnosis of an RA, axSpA or GCA
  • - Stable, flare-free disease status within the last 6 month prior to enrollment.
  • - Shingrix zoster vaccination planned in routine care based on approval of Shingrix

排除标准

  • - Pregnancy
  • - Episode of zoster in the past 6 months
  • - Inability to give consent
  • - Previous live vaccination against shingles
  • - VZV vaccination within 12 months prior to start of the study
  • - Contraindications to vaccination: Allergies to components of the vaccine. Undesirable drug reactions in the temporal connection with the vaccination are also a contraindication against a repeated vaccination with the same vaccine until the cause is clarified.

研究者

相似试验